UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline
Source: SeekingAlpha
2026-03-02 12:58:34 ET
More on UroGen Pharma
- UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on UroGen Pharma
- Historical earnings data for UroGen Pharma
- Financial information for UroGen Pharma
Read the full article on Seeking Alpha
For further details see:
UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline
UroGen Pharma Ltd.
NASDAQ: URGN
URGN Trading
-3.2% G/L:
$19.36 Last:
393,329 Volume:
$20.11 Open:
URGN Latest News
URGN Stock Data
$1,013,880,601
41,940,767
0.31%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
